EP1590431A4 - TNF-a BINDING MOLECULES - Google Patents

TNF-a BINDING MOLECULES

Info

Publication number
EP1590431A4
EP1590431A4 EP04700833A EP04700833A EP1590431A4 EP 1590431 A4 EP1590431 A4 EP 1590431A4 EP 04700833 A EP04700833 A EP 04700833A EP 04700833 A EP04700833 A EP 04700833A EP 1590431 A4 EP1590431 A4 EP 1590431A4
Authority
EP
European Patent Office
Prior art keywords
tnf
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04700833A
Other languages
German (de)
French (fr)
Other versions
EP1590431A2 (en
Inventor
Jeffry D Watkins
Alain P Vasserot
David Marquis
William D Huse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/338,552 external-priority patent/US7101978B2/en
Priority claimed from US10/338,627 external-priority patent/US20040131613A1/en
Application filed by Applied Molecular Evolution Inc filed Critical Applied Molecular Evolution Inc
Publication of EP1590431A2 publication Critical patent/EP1590431A2/en
Publication of EP1590431A4 publication Critical patent/EP1590431A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP04700833A 2003-01-08 2004-01-08 TNF-a BINDING MOLECULES Withdrawn EP1590431A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/338,552 US7101978B2 (en) 2003-01-08 2003-01-08 TNF-α binding molecules
US338552 2003-01-08
US10/338,627 US20040131613A1 (en) 2003-01-08 2003-01-08 TNF-alpha binding molecules
US338627 2003-01-08
PCT/US2004/000290 WO2004063335A2 (en) 2003-01-08 2004-01-08 TNF-α BINDING MOLECULES

Publications (2)

Publication Number Publication Date
EP1590431A2 EP1590431A2 (en) 2005-11-02
EP1590431A4 true EP1590431A4 (en) 2009-12-23

Family

ID=32716888

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04700833A Withdrawn EP1590431A4 (en) 2003-01-08 2004-01-08 TNF-a BINDING MOLECULES

Country Status (3)

Country Link
EP (1) EP1590431A4 (en)
JP (1) JP2007525409A (en)
WO (1) WO2004063335A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN102127167B (en) * 2010-01-15 2013-06-19 苏州工业园区晨健抗体组药物开发有限公司 Whole human TNF alpha (tumor necrosis factor alpha) monoclonal antibody and preparation and application thereof
CN102336834B (en) * 2010-07-22 2014-01-01 苏州工业园区晨健抗体组药物开发有限公司 Fully human TNFalpha-Fab antibody and its PEG antibody
SG11201401774VA (en) 2011-10-24 2014-10-30 Abbvie Inc Immunobinders directed against tnf

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626389A1 (en) * 1990-12-21 1994-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNF-alpha
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626389A1 (en) * 1990-12-21 1994-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNF-alpha
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)

Also Published As

Publication number Publication date
WO2004063335A2 (en) 2004-07-29
WO2004063335A3 (en) 2009-06-04
EP1590431A2 (en) 2005-11-02
JP2007525409A (en) 2007-09-06

Similar Documents

Publication Publication Date Title
ZA201301416B (en) Binding molecules
HK1096578A1 (en) Cd20 binding molecules cd20
IL173820A0 (en) Therapeutic binding molecules
GB0510790D0 (en) Anti-CD16 binding molecules
ZA200810117B (en) Cripto binding molecules
EP1907001A4 (en) Ilt3 binding molecules and uses therefor
SG128680A1 (en) Binding molecules against sars-coronavirus and uses thereof
HK1146645A1 (en) Chemically modified small molecules
GB0601513D0 (en) Binding molecules 3
EP1981538A4 (en) Metalloproteinase binding proteins
ZA200801389B (en) II-6 Binding proteins
IL166361A0 (en) Binding molecules
EP1966603A4 (en) Binding of molecules
GB2405854B (en) Booklet
GB0601511D0 (en) Binding Molecules 2
ZA200407185B (en) Binding element.
EP1590431A4 (en) TNF-a BINDING MOLECULES
GB0410983D0 (en) Molecules
AU2003209753A1 (en) Internalising human binding molecules against cd72
AU2003201559A8 (en) Multispecific binding molecules
GB0327532D0 (en) Specific binding molecules
GB0406342D0 (en) Molecules
GB0306185D0 (en) Molecules
GB0219013D0 (en) Modified integration binding molecules
GB0511881D0 (en) Binding molecules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101ALI20090921BHEP

Ipc: A61K 39/395 20060101AFI20090921BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091119

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/06 20060101ALI20091113BHEP

Ipc: A61K 39/395 20060101ALI20091113BHEP

Ipc: C07K 16/24 20060101AFI20091113BHEP

17P Request for examination filed

Effective date: 20091204

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20091228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100508